O steocytes are the most abundant cell type in the bone, comprising more than 90% of all cells within the bone matrix or on bone surfaces. Osteocytes are derived from osteoblasts and are entombed in the bone matrix during bone deposition. Osteocytes were originally thought to be rather inert cells whose function was limited to maintaining bone matrix locally. However, osteocytes are connected to other bone cells, endothelial cells, and hematopoietic cells near endosteal surfaces through an extensive network of canaliculi through which cytoplasmic projections of osteocytes travel. This network allows for the transport of proteins produced by osteocytes to act on cells in the bone marrow cavity. For example, osteocyte production of sclerostin and RANK ligand are key regulators of osteoblast and osteoclast activity, respectively (see figure) . 2, 3 Because osteoblasts have been implicated in hematopoietic stem cell and B-cell maintenance, these observations suggested the hypothesis that signals generated by osteocytes contribute to the regulation of hematopoiesis.
To test the hypothesis, Fulzele and colleagues generated mice with a conditional deletion of G␣S in osteocytes. G␣S is an obligate subunit of several G protein-coupled receptors that are expressed in osteocytes. Surprisingly, deletion of G␣S in osteocytes resulted in a myeloproliferative-like syndrome characterized by neutrophilia, thrombocytosis, and splenomegaly. However, unlike human myeloproliferative syndromes, the hematopoietic abnormalities did not result in increased mortality or leukemic transformation. This phenotype was secondary to an altered bone marrow microenvironment, because G␣S-osteocytesdeleted mice transplanted with wild-type bone marrow rapidly developed a myeloproliferative phenotype. Indeed, deletion of G␣S in osteocytes results in osteocyte expansion, loss of osteoblasts, and osteopenia. The authors show that increased osteocytes expression of sclerostin, a potent Wnt antagonist, is responsible for the loss of osteoblasts. However, sclerostin and osteoblast loss are not required for the myeloproliferative phenotype, because treatment with a sclerostin-neutralizing antibody, while rescuing the osteoblast defect, did not correct the leukocytosis.
The authors next established a novel ex vivo co-culture system using osteocyteenriched bone explants to look for secreted factors that promote myeloid progenitor proliferation. These studies led to the discovery that osteocytes produce large amounts of granulocyte colony-stimulating factor (G-CSF), the principal cytokine regulating granulopoiesis. Although not tested in vivo, neutralizing antibodies to G-CSF inhibited the ability of osteocyte-conditioned media to stimulate myeloid progenitor growth in vitro, providing direct evidence that G-CSF, at least partially, drives the myeloproliferative phenotype in G␣S-osteocytes-deleted mice. Consistent with this conclusion, transgenic mice For personal use only. on April 8, 2017. by guest www.bloodjournal.org From that constitutively overexpress G-CSF develop a nonfatal myeloproliferative phenotype that is very similar to that observed in G␣S-osteocytes-deleted mice, including neutrophilia, splenomegaly, and osteopenia. 4 This provocative study raises several important questions. The authors show that impaired parathyroid home/parathyroid hormone-related protein receptor signaling in osteocytes is not responsible for the MPD-like phenotype. Which, then, of the approximately 50 G protein-coupled receptors that are expressed in osteocytes, are responsible for the myeloproliferative-like phenotype? While likely contributing to the neutrophilia, the elevated level of G-CSF is unlikely to cause thrombocytosis, and the factor(s) that are stimulating thrombopoiesis are unclear. Finally, these data raise the possibility that inherited disorders of osteocytes may contribute to the pathogenesis of certain blood disorders.
The important study by Fulzele and colleagues adds osteocytes to the list of bone marrow stromal cells that regulate hematopoiesis. Osteocytes play an essential role in sensing and responding to mechanical stress on bone. Thus, osteocytes may provide a mechanism by which mechanical and other stresses on bone regulate hematopoiesis.
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In this issue of Blood, Loria and colleagues present new aspects on the role of platelets in protecting against both lethal hemorrhagic diathesis and virus replication in viral hemorrhagic fever (VHF), using a murine model of lymphocytic choriomeningitis virus (LMCV) infection. 1 T he natural mouse pathogen LCMV is a member of the Arenaviridae family that sporadically infects humans. Several arenaviruses are etiologic agents of VHF in humans, a syndrome characterized by fever, headache, general malaise, impaired cellular immunity, and hemostatic alterations including thrombocytopenia that may ultimately lead to shock and death. 2 Clinical manifestations of VHF are not fully recapitulated in mice after infection with any arenavirus, including LCMV. This limits the utility of this animal model in studying the pathogenic mechanisms of bleeding disorders observed in human VHF. Infection of adult mice with the Armstrong LCMV strain induces a fully protective cytotoxic T lymphocyte (CTL) response that is able to clear the infection within 1 week. In contrast, other LCMV strains such as clone-13 produce an acute thrombocytopenia without bleeding, and chronic, persistent infection occurs with the virus replicating to high titers in multiple organs associated with a deficient CTL response. Although subtle changes in host cell function occur with LCMV replication, LCMV is essentially considered to be a noncytolytic virus that indicates that the major signs of LCMV-associated pathology are mostly attributable to the host response to infection. 3 In 2008, 2 major advances shed light on the role of platelets in VHF, using mice as experimental models. First, it was demonstrated that mice rendered thrombocytopenic only suffered localized hemorrhages at sites undergoing noninfectious inflammatory processes, and that low numbers of circulating platelets were able to prevent such inflammation-induced hemorrhages. 4 Second, Iannacone et al reported that platelet-depleted mice infected with the LCMV Armstrong strain developed a syndrome similar to VHFs, with mucocutaneous bleeding, vascular leakage, anemia, uncontrolled viral replication, suboptimal immune responses, and animal death. 5 Remarkably, lethal hemorrhage was less associated with thrombocytopenia and instead was more closely associated with platelet dysfunction mediated by high interferon (IFN)-I levels.
In the current paper, Loria et al induced a finely tuned platelet depletion using antibodies, and confirmed and extended previous findings. They show that mice profoundly depleted of platelets (Ͼ 95% depletion) and infected with the Armstrong LCMV strain developed hemorrhagic spots in several organs along with high viral titers, generalized splenic necrosis, and increased mortality. Interestingly, they also found that the presence of 15% of platelets (partial depletion) was sufficient to prevent vascular damage but not viral replication, necrotic destruction of innate and adaptive immune splenocytes, or CTL exhaustion. These observations not only confirm the novel notion that platelets are necessary to protect vascular integrity and are critical mediators of viral clearance, but also underscore an underappreciated relationship among plateletmediated hemostasis, viral infection, and immunosuppression. Furthermore, the authors perceptively suggest that the higher circulating platelet levels in humans compared with other species explain why mice are not suitable experimental models to study VHF and offer a simple alternative model to study the pathophysiology of VHF and other infectious diseases.
Different platelet requirements for controlling vascular integrity and immune response is an interesting novel concept and suggests that these 2 events may involve different platelet-mediated mechanisms. Based on the recent findings concerning platelet maintenance of vascular integrity, 4 Loria et al suggest that the extreme efficiency of a small number of platelets in preventing these vascular defects may involve delivery to the endothelium vasoactive compounds from the platelet granules rather than platelet adhesion or aggregation. On the other hand, the marked disarray of the splenic cytoarchitecture allows profuse transmigration of immune cells that may open holes in the vascular wall and promote platelet 868 BLOOD, 7 FEBRUARY 2013 ⅐ VOLUME 121, NUMBER 6
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